Multiple sclerosis: Benefits of alemtuzumab in MS

Nature Reviews Neurology

Volumn 7, Issue 5, 2011, Pages 245-

  Wood, Heather ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON;

AGE; BRAIN ATROPHY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NOTE; PHYSICAL DISABILITY; PRIORITY JOURNAL; RELAPSE; RISK REDUCTION;

EID: 79955834495     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.57     Document Type: Note

References (1)

1. Coles, A. J. et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 10, 338-348 (2011)